This site is intended for healthcare professionals

Omega-3-acid ethyl ester medicines: MHRA update

Posted 19 Apr 2024

Dr Anish Kotecha FRCGP FAcadMEd GPwERLM MBBCh BSc

Dr Anish Kotecha summarises a recent safety update from the MHRA regarding the use of omega-3-acid ethyl ester medicines in patients with cardiovascular disease or cardiovascular risk factors.

Reference

(1) MHRA. 2024. https://www.gov.uk/drug-safety-update/omega-3-acid-ethyl-ester-medicines-omacor-slash-teromeg-1000mg-capsules-dose-dependent-increased-risk-of-atrial-fibrillation-in-patients-with-established-cardiovascular-diseases-or-cardiovascular-risk-factors

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page